Asthma Accounts for About 250,000 Deaths around the World Annually, Claims GlobalData

19 Jun 2013 • by Natalie Aster

In 2012, there were 135.28 million lifetime prevalent cases of asthma in the 10 major markets, with approximately 80.00 million cases in the US (41.90 million cases) and India (39.00 million cases) combined. There will be approximately 159.20 million lifetime prevalent cases of asthma in the 10 major markets by 2022, with an overall growth of 17.7% over the next decade.

Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term condition characterized by narrowing of the airways, leading to airflow limitation and airway hyper-responsiveness whenever the lungs come into contact with endogenous and exogenous irritants. Exposure to irritants instigates a series of events, such as swelling of the airways, tightening of the respiratory muscles, and increased mucus production, leading to reduced airflow into the lungs. These chain reactions within the airways lead to the symptoms of asthma, which are often paroxysmal or persistent, such as recurring periods of coughing, wheezing (whistling sound when breathing), breathlessness, and chest tightness (NHS, 2013; NIH, 2012a).

The “EpiCast Report: Asthma - Epidemiology Forecast to 2022” report by GlobalData estimated that 300 million people suffered from asthma worldwide, with the prevalence varying widely in different countries. However, recent trends show that the disparity is narrowing due to the rising prevalence of asthma in developing countries and the plateauing prevalence in developed countries. Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment (Masoli et al., 2004; WHO, 2007).

Report Details:

EpiCast Report: Asthma - Epidemiology Forecast to 2022
Published: May, 2013
Pages: 79
Price: US$ 3,995.00

To summarize, GlobalData’s epidemiological forecast predicted a substantial increase in the lifetime prevalent cases of asthma in all of the markets, except for Germany and Japan. The epidemiologists attribute the growth in the prevalent cases of asthma to changing population demographics in all the markets, except for the US and the UK, where this growth is also attributed to trends in both genetic determinants and environmental factors. In addition, GlobalData’s analysis demonstrates the increasing social burden of asthma in these markets and the growing necessity for healthcare providers, policymakers, and states to plan effective clinical and public health strategies. To conclude, governments should focus more on educating people about avoiding the risks for asthma and managing their symptoms, so they can live longer and more productive lives while reducing healthcare costs (de Marco et al., 2012).

More information can be found in the report “EpiCast Report: Asthma - Epidemiology Forecast to 2022” by GlobalData.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970